About Abingdon Health
Abingdon Health is a publicly listed company based in York (United Kingdom) founded in 2008. Developer of immunoassays for diagnostic purposes. Abingdon Health has raised $24.05 million across 8 funding rounds from investors including Mercia and Imperial Innovations. Abingdon Health has completed 2 acquisitions, including Compliance Solutions and Molecular Vision. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Blood Cancer. Its legal entity is ABINGDON HEALTH PLC.
Company details
Abingdon Health was founded in 2008 in York, United Kingdom, within the diagnostics sector. Rapid lateral flow immunoassay systems enabling multiplexed immunodiagnostics are developed by the company. The flagship product, Seralite-FLC, measures kappa and lambda immunoglobulin-free light chains to detect hematological cancers. Research services are offered across clinical point-of-care, self-testing, pharmaceutical, and related sectors.
- Headquarters York, United Kingdom
- Stage Public
- SectorsHealthcare
- Website abingdonhealth.com
- Social LinkedIn X YouTube
- Legal Name Abingdon Health Plc
- Annual Revenue$11.55 M (USD)37.39as on Jun 30, 2025
- Net Profit-$4.69 M (USD)-168.69as on Jun 30, 2025
- EBITDA-$4.69 M (USD)-137.46as on Jun 30, 2025
- Total Equity Funding$24.05M (USD)
in 8 rounds
- Latest Funding Round$4.4M (USD), Post-IPO
Oct 2025
- InvestorsMercia
& 1 more
- Investments & AcquisitionsCompliance Solutions
& 1 more
Apps and channels of Abingdon Health
its YouTube channel Abingdon Health has 2.29K subscribers and 9 videos.
Videos from Abingdon Health
The most watched videos on Abingdon Health's YouTube channel, Abingdon Health (2.29K subscribers). Click a video to play it here.
More on Abingdon Health.
Funding Insights of Abingdon Health
Abingdon Health has successfully raised a total of $24.05M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.4 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.05M
- Total Rounds 8
- Last Round Post-IPO — $4.4M
- First Round $3.18M
(Mar 2012)
- Investors Count 2
All 8 funding rounds of Abingdon Health with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $4.4M | Post-IPO | – | – | – |
| Jan 2019 | $2.64M | Series A | – | Mercia | – |
| Dec 2017 | $1.5M | Series A | – | – | – |
| Jul 2016 | $3.88M | Series A | – | Imperial Innovations | – |
| Jun 2015 | $4.72M | Series A | – | Imperial Innovations | – |
| Oct 2014 | $3.38M | Series A | – | Imperial Innovations | – |
| May 2012 | $4.76M | Series A | – | Imperial Innovations | – |
| Mar 2012 | $3.18M | Series A | – | Imperial Innovations | – |
2 investors in total: 2 institutional.
Investors in Abingdon Health
Abingdon Health has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Mercia and Imperial Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in startups are focused on Europe and the US. | 1986 | imperialinnovations.co.uk | London, United Kingdom | |
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk |
Investor details for Abingdon Health
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abingdon Health
28 people are tracked at Abingdon Health (6 in leadership, 5 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Mark Jones | Chief Operating Officer | Leadership |
Candice Vendettuoli | Quality & Regulatory Affairs Director | Leadership |
Rob Edwards | Head Of Customer Experience | Leadership |
Chris Yates | President, Abingdon Health USA Inc And Chief Commercial Officer, Abingdon Health Plc | Leadership |
Nina Garrett | Chief Technical Officer | Leadership |
Natalie Thrush | Head of HR | Leadership |
Chris Hand | Chairman | Board & advisors |
Mike Holmes | Medical Advisor | Board & advisors |
Mary Tavener | Director | Board & advisors |
Lawrence S. Young | Scientific Advisor | Board & advisors |
Tara Moore | Scientific Advisor | Board & advisors |
Ryan Hannam | Analytical Performance Lead | Team |
Nathan Sharlotte | Research And Development Scientist | Team |
Tom Lee | Research And Development Scientist | Team |
Robin Brazier | Research And Development Scientist | Team |
James Clarke | Supply Chain Manager | Team |
Gillian Surr | Senior Project Manager | Team |
Amanda Nicholl | Lead Project Manager | Team |
Stephanie Mabin | Production Technical Manager | Team |
Nicole Turner | Quality Manager | Team |
8 more people are available in the full profile.
Complete people profiles for Abingdon Health
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Abingdon Health
Abingdon Health is a publicly listed company on the LSE with ticker symbol ABDX in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Dec 2020
- Listed onLSE: ABDX
- Listed entityAbingdon Health PLC
- Exchange sectorHealth technology
- ISINGB00BLF79J41
- Share price9.50 GBX · 2026-10-14
- Market capitalisation24,011,390.00 GBX
- EPS (diluted, trailing year)-0.01 GBX
- Volume (last session)100,400
Financials of Abingdon Health
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 8.4M GBP | -3.4M GBP | -3.4M GBP |
| 2024 | 6.1M GBP | -1.3M GBP | -1.4M GBP |
| 2023 | 4.0M GBP | -3.5M GBP | -3.2M GBP |
| 2022 | 2.8M GBP | -21.3M GBP | -10.5M GBP |
| 2021 | 11.6M GBP | -7.0M GBP | -4.8M GBP |
Detailed financial statements for Abingdon Health
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abingdon Health
Abingdon Health has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Compliance Solutions and Molecular Vision.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Consultancy firm providing regulatory advice and compliance services to life science companies, specializing in medical devices, IVD, and pharmaceuticals | cslifesciences.com | Glasgow, United Kingdom | 2008 | Aug 2024 | •••• | |
Optical detection platforms for portable medical diagnostics are developed. | molecularvision.co.uk | London, United Kingdom | 2001 | Mar 2012 | •••• |
Complete acquisition details for Abingdon Health
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abingdon Health
6 dated milestones of Abingdon Health across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Abingdon Health is founded.
- Acquisition Acquires Molecular Vision.
- Funding First funding round of $3.2M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Compliance Solutions.
- Funding Latest funding round, Post-IPO, of $4.4M.
Web traffic of Abingdon Health
The website of Abingdon Health (abingdonhealth.com) receives about 9.5K visits a month.
- Monthly visits9.5K
▲ 67.3% vs previous month
Websites whose visitors overlap most with Abingdon Health. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| dcndx.com | 100% | 8.6K | #2,703,307 | View details | |
| innovabiosciences.com | 97% | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Abingdon Health (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abingdon Health
Complete news archive for Abingdon Health
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abingdon Health
Abingdon Health was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Abingdon Health is headquartered in York, United Kingdom.
Abingdon Health is a funded company, having raised a total of $24.05M across 8 funding rounds to date. The company's 1st funding round was a Series A of $3.18M, raised on Mar 2012.
Annual revenue of Abingdon Health is $11.55M as on Jun 30, 2025.
Abingdon Health was founded in 2008 in York, United Kingdom, within the diagnostics sector. Rapid lateral flow immunoassay systems enabling multiplexed immunodiagnostics are developed by the company. The flagship product, Seralite-FLC, measures kappa and lambda immunoglobulin-free light chains to detect hematological cancers. Research services are offered across clinical point-of-care, self-testing, pharmaceutical, and related sectors.
Yes, Abingdon Health is publicly traded on LSE under the ticker symbol ABDX.
Abingdon Health has made 2 acquisitions, including Compliance Solutions, and Molecular Vision.
Abingdon Health has 2 investors. Key investors include Mercia, and Imperial Innovations.
Abingdon Health operates through Abingdon Health Plc.